BioSpace News Archive

Aims to create immune cells with significantly larger DNA payloads encoding synthetic biological instructions to overcome solid tumors’ complex defense systems

RTI will host a conference call and simultaneous audio webcast to discuss third quarter results at 9:00 a.m. ET the same day.

Daiichi Sankyo Company, Limited and AstraZeneca announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for [fam-] trastuzumab deruxtecan and granted Priority Review..

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus (RSE) were presented at the Neurocritical Care Society 17th Annual Meeting in Vancouver, BC.

Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting data showing the increasing utility of genetic information at the American Society of Human Genetics (ASHG) annual meeting this week, ranging from comprehensive screening for cancer patients, to appropriate clinical follow up for women using non-invasive prenatal screening, to the limitations of direct to consumer genetic screening health reports.

Data show how gp-ASIT+™, administered in a pre-seasonal 3-week treatment, is able to rapidly modulate the cellular response and induce production of blocking antibodies. This effect led to a significant reduction in the combined clinical symptom and medication score during the following pollen season.

Elekta announces that its Elekta Unity magnetic resonance radiation therapy system has been awarded the Institute of Physics Business Innovation Award 2019.

Myovant Sciences announced the formation of Female Forward Together, a cross-sector coalition bringing together expertise in healthcare, research, data science, digital health, and advocacy to improve women’s health.

Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by Myovant Sciences, a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, and Evidation Health, a health and measurement company that helps life sciences companies understand how everyday behavior and health interact.

CATALIS Québec launches a promotional campaign to demonstrate Quebec’s expertise in the conduct of early-phase clinical trials and to encourage new partnerships between the biopharmaceutical industry and university research centres.